With a huge population the Asia Pacific region is becoming an area of focus for the conduct of clinical trials. In line with this orphan reach has expanded its operations into countries like India, China and the wider Pacific Rim.
Aside from the obvious recruitment potential arising from populations in excess of one billion people, in the likes of India and China, the Asia Pacific region offers a vast array of diseases.
Furthermore, the cost of conducting clinical research in the region can be up to 50% cheaper compared to the US and Western Europe. This coupled with the already highly cost effective orphan reach model provides a significant budgetary advantage.
Quality and compliance are of course fundamental factors and often there can be a perception, similarly to the opening up of Central Eastern Europe for the conduct of clinical research, that this is an issue within an emerging region such as Asia Pacific. Many sites across the region are already fully ICH GCP trained and compliant and orphan reach work closely with our operational teams on the ground to evaluate this before including any sites in our sponsor’s projects.
This local knowledge and direct contact on the ground are critical to the successful conduct of clinical studies in the Asia Pacific region and reinforces why you can count on orphan reach to deliver your project in this region.